Search

Your search keyword '"Iacona, C"' showing total 2 results
Start Over Author "Iacona, C" Journal british journal of haematology
2 results on '"Iacona, C"'

1. MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study

Author

Ilaria Francaviglia, Paolo Lopedote, Filippo Gagliardi, Fabio Ciceri, Sara Steffanoni, Rita Daverio, Teresa Calimeri, Elena Anghileri, Maria Rosa Terreni, Marianna Sassone, Roberto Furlan, Piera Angelillo, Vittoria Tarantino, Maurilio Ponzoni, Chiara Iacona, Claudio Tripodo, Cristina Belloni, Alessandro Gulino, Daniela De Lorenzo, Massimo Filippi, Marica Eoli, Elena Guggiari, Maria Giulia Cangi, Vittorio Martinelli, Massimo Locatelli, Annamaria Finardi, Andrés J.M. Ferreri, Andrea Falini, Nicoletta Anzalone, Marco Foppoli, Alessandro Nonis, Pietro Mortini, Claudio Doglioni, Angelo Diffidenti, Ferreri, A. J. M., Calimeri, T., Lopedote, P., Francaviglia, I., Daverio, R., Iacona, C., Belloni, C., Steffanoni, S., Gulino, A., Anghileri, E., Diffidenti, A., Finardi, A., Gagliardi, F., Anzalone, N., Nonis, A., Furlan, R., De Lorenzo, D., Terreni, M. R., Martinelli, V., Sassone, M., Foppoli, M., Angelillo, P., Guggiari, E., Falini, A., Mortini, P., Filippi, M., Tarantino, V., Eoli, M., Ciceri, F., Doglioni, C., Tripodo, C., Locatelli, M., Cangi, M. G., Ponzoni, M., Ferreri A.J.M., Calimeri T., Lopedote P., Francaviglia I., Daverio R., Iacona C., Belloni C., Steffanoni S., Gulino A., Anghileri E., Diffidenti A., Finardi A., Gagliardi F., Anzalone N., Nonis A., Furlan R., De Lorenzo D., Terreni M.R., Martinelli V., Sassone M., Foppoli M., Angelillo P., Guggiari E., Falini A., Mortini P., Filippi M., Tarantino V., Eoli M., Ciceri F., Doglioni C., Tripodo C., Locatelli M., Cangi M.G., and Ponzoni M.

Subjects
Adult, Male, Pathology, medicine.medical_specialty, Lymphoma, Biopsy, Concordance, interleukin-10, diffuse large B-cell lymphoma, Mutation, Missense, Central Nervous System Neoplasms, 03 medical and health sciences, primary CNS lymphoma, 0302 clinical medicine, Cerebrospinal fluid, hemic and lymphatic diseases, Biomarkers, Tumor, TaqMan, medicine, Humans, diffuse large B-cell lymphoma, interleukin-10, interleukin-6, MYD88 L265P mutation, primary CNS lymphoma, Prospective cohort study, Aged, medicine.diagnostic_test, business.industry, interleukin-6, Primary central nervous system lymphoma, Hematology, Middle Aged, medicine.disease, Interleukin-10, Neoplasm Proteins, MYD88 L265P mutation, Amino Acid Substitution, 030220 oncology & carcinogenesis, Myeloid Differentiation Factor 88, Female, business, Diffuse large B-cell lymphoma, 030215 immunology
Abstract

Reliable biomarkers are needed to avoid diagnostic delay and its devastating effects in patients with primary central nervous system (CNS) lymphoma (PCNSL). We analysed the discriminating sensitivity and specificity of myeloid differentiation primary response (88) (MYD88) L265P mutation (mut-MYD88) and interleukin-10 (IL-10) in cerebrospinal fluid (CSF) of both patients with newly diagnosed (n=36) and relapsed (n=27) PCNSL and 162 controls (118 CNS disorders and 44 extra-CNS lymphomas). The concordance of MYD88 mutational status between tumour tissue and CSF sample and the source of ILs in PCNSL tissues were also investigated. Mut-MYD88 was assessed by TaqMan-based polymerase chain reaction. IL-6 and IL-10 messenger RNA (mRNA) was assessed on PCNSL biopsies using RNAscope technology. IL levels in CSF were assessed by enzyme-linked immunosorbent assay. Mut-MYD88 was detected in 15/17 (88%) PCNSL biopsies, with an 82% concordance in paired tissue-CSF samples. IL-10 mRNA was detected in lymphomatous B cells in most PCNSL; expression of IL-6 transcripts was negligible. In CSF samples, mut-MYD88 and high IL-10 levels were detected, respectively, in 72% and 88% of patients with newly diagnosed PCNSL and in 1% of controls; conversely, IL-6 showed a low discriminating sensitivity and specificity. Combined analysis of MYD88 and IL-10 exhibits a sensitivity and specificity to distinguish PCNSL of 94% and 98% respectively. Similar figures were recorded in patients with relapsed PCNSL. In conclusion, high detection rates of mut-MYD88 and IL-10 in CSF reflect, respectively, the MYD88 mutational status and synthesis of this IL in PCNSL tissue. These biomarkers exhibit a very high sensitivity and specificity in detecting PCNSL both at initial diagnosis and relapse. Implications of these findings in patients with lesions unsuitable for biopsy deserve to be investigated.

Published
2021
Full Text
View/download PDF

2. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.

Author

Ferreri AJM, Calimeri T, Lopedote P, Francaviglia I, Daverio R, Iacona C, Belloni C, Steffanoni S, Gulino A, Anghileri E, Diffidenti A, Finardi A, Gagliardi F, Anzalone N, Nonis A, Furlan R, De Lorenzo D, Terreni MR, Martinelli V, Sassone M, Foppoli M, Angelillo P, Guggiari E, Falini A, Mortini P, Filippi M, Tarantino V, Eoli M, Ciceri F, Doglioni C, Tripodo C, Locatelli M, Cangi MG, and Ponzoni M

Subjects
Adult, Aged, Amino Acid Substitution, Biopsy, Female, Humans, Interleukin-10 genetics, Male, Middle Aged, Myeloid Differentiation Factor 88 cerebrospinal fluid, Biomarkers, Tumor cerebrospinal fluid, Biomarkers, Tumor genetics, Central Nervous System Neoplasms cerebrospinal fluid, Central Nervous System Neoplasms genetics, Central Nervous System Neoplasms pathology, Interleukin-10 cerebrospinal fluid, Lymphoma cerebrospinal fluid, Lymphoma genetics, Mutation, Missense, Myeloid Differentiation Factor 88 genetics, Neoplasm Proteins cerebrospinal fluid, Neoplasm Proteins genetics
Abstract

Reliable biomarkers are needed to avoid diagnostic delay and its devastating effects in patients with primary central nervous system (CNS) lymphoma (PCNSL). We analysed the discriminating sensitivity and specificity of myeloid differentiation primary response (88) (MYD88) L265P mutation (mut-MYD88) and interleukin-10 (IL-10) in cerebrospinal fluid (CSF) of both patients with newly diagnosed (n = 36) and relapsed (n = 27) PCNSL and 162 controls (118 CNS disorders and 44 extra-CNS lymphomas). The concordance of MYD88 mutational status between tumour tissue and CSF sample and the source of ILs in PCNSL tissues were also investigated. Mut-MYD88 was assessed by TaqMan-based polymerase chain reaction. IL-6 and IL-10 messenger RNA (mRNA) was assessed on PCNSL biopsies using RNAscope technology. IL levels in CSF were assessed by enzyme-linked immunosorbent assay. Mut-MYD88 was detected in 15/17 (88%) PCNSL biopsies, with an 82% concordance in paired tissue-CSF samples. IL-10 mRNA was detected in lymphomatous B cells in most PCNSL; expression of IL-6 transcripts was negligible. In CSF samples, mut-MYD88 and high IL-10 levels were detected, respectively, in 72% and 88% of patients with newly diagnosed PCNSL and in 1% of controls; conversely, IL-6 showed a low discriminating sensitivity and specificity. Combined analysis of MYD88 and IL-10 exhibits a sensitivity and specificity to distinguish PCNSL of 94% and 98% respectively. Similar figures were recorded in patients with relapsed PCNSL. In conclusion, high detection rates of mut-MYD88 and IL-10 in CSF reflect, respectively, the MYD88 mutational status and synthesis of this IL in PCNSL tissue. These biomarkers exhibit a very high sensitivity and specificity in detecting PCNSL both at initial diagnosis and relapse. Implications of these findings in patients with lesions unsuitable for biopsy deserve to be investigated., (© 2021 British Society for Haematology and John Wiley & Sons Ltd.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results